Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Details
News Market Reaction – HAE
The recorded move for HAE in the trading session of this news was +1.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Financial release accessible online
The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 8, 2023. The conference call and webcast can be accessed with the following information:
- Teleconference link: https://register.vevent.com/register/BI161cbc44c95c40ac857474a72c5ba4c0
- Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
- A live webcast of the call can be accessed on Haemonetics' investor relations website or via the following link: https://edge.media-server.com/mmc/p/y8b7kg5q
In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.
Direct link to 1Q FY24 Earnings Release:
https://haemonetics.gcs-web.com/static-files/59d8e57d-0800-42fb-9047-72f4fac27a89
A replay of the conference call and webcast will be available for one year beginning on August 8, 2023, at 11:00 a.m. ET using the conference call webcast link provided in this press release.
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Sr. Director-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-1st-quarter-fiscal-year-2024-earnings-release-available-on-investor-relations-website-301895394.html
SOURCE Haemonetics Corporation